Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 125-133

  Agarwala, S S ^a   Glaspy, J ^a   O'Day, S J ^a   Mitchell, M ^a   Gutheil, J ^a   Whitman, E ^a   Gonzalez, R ^a   Hersh, E ^a   Feun, L ^a   Belt, R ^a   Meyskens, F ^a   Hellstrand, K ^a   Wood, D ^a   Kirkwood, J M ^a   Gehlsen, K R ^a   Naredi, P ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE; INTERLEUKIN 2; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL ACTIVATION; CLINICAL TRIAL; COMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPOTENSION; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; NATURAL KILLER CELL; NAUSEA; PHAGOCYTE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSUMER PRODUCT SAFETY; DRUG SYNERGISM; FEMALE; HISTAMINE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; UNITED STATES;

EID: 0036137546     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.125     Document Type: Article

References (34)

1. Cancer Statistics, 2001
2. Prognostic factors in 1,521 melanoma patients with distant metastases
3. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
4. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
5. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T celland natural killer cell-mediated cytotoxicity
6. Histaminergic regulation of NK cells: Role of monocyte-derived reactive oxygen metabolites
7. Histamine protects T cells and natural killer cells against oxidative stress
8. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites
9. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors
10. Synergistic NK cell activation by histamine and interleukin-2
11. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice
12. The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation
13. Interleukin-2 and histamine in combination inhibit tumor growth and angiogenesis in malignant glioma
14. Histamine in immunotherapy of advanced melanoma: A pilot study
15. Histamine in cancer immunotherapy
16. An analysis of prognostic factors in 4000 patients with cutaneous melanoma
17. Multiple comparison procedures updated
18. Cutaneous melanoma Cancer: Principles and Practice of Oncology
19. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
20. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study
21. Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients
22. Dacarbazine, cisplatin and IFN-alfa with or without IL-2 in advanced melanoma (EORTC trial 18951)
23. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2B (INF) versus CVD in patients (pts) with metastatic melanoma
24. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: Role of reactive oxygen species and regulation by histamine
25. Histamine and cytokine therapy
26. Histamine and interleukin-2 in acute myelogenous leukemia
27. Histamine: A novel approach to cancer immunotherapy
28. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study
29. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
30. Continuous infusion recombinant interleukin-2 (rIL-1) in adoptive cellular therapy of renal carcinoma and other malignancies
31. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma
32. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
33. Randomized phase III trial of treatment with high dose interleukin-2 alone or in combination with interferon alfa-2a in patients with advanced melanoma
34. Cutaneous melanoma: Current practice and surgical controversies